共 50 条
- [21] Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)van de Donk, Niels W. C. J.Garfall, Alfred L.Benboubker, LotfiUttervall, KatarinaGroen, KazRosinol, LauraMatous, Jeffrey V.Vishwamitra, DeekshaHodin, CarolineStephenson, TaraQi, KeqinZuppa, AthenaChastain, KatherineMateos, Maria-Victoria
- [22] Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 studyCANCER, 2024, 130 (06) : 886 - 900Nooka, Ajay K.Rodriguez, CesarMateos, Maria VictoriaManier, SalomonChastain, KatherineBanerjee, ArnobKobos, RachelQi, KeqinVerona, RalucaDoyle, MargaretMartin, Thomas G.van de Donk, Niels W. C. J.
- [23] Nursing Considerations for Cytokine Release Syndrome in Relapsed/ Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 StudySEMINARS IN ONCOLOGY NURSING, 2024, 40 (03)Catamero, DonnaBenito, Patricia BlazquezShenoy, SamanthaDoyle, MargaretFowler, JessicaKobos, RachelBanerjee, ArnobKruyswijk, Sandy
- [24] Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S477 - S477Usmani, Saad Z.Karlin, LionelBenboubker, LotfiNahi, HarethSan-Miguel, JesusTrancucci, DanielleQi, KeqinStephenson, TaraPuchalt, Alfredo PeralesChastain, KatherineChari, Ajai
- [25] Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: a Subgroup Analysis From the Phase 1/2 MajesTEC-1 StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S546 - S547Costa, Luciano J.Bahlis, Nizar J.Usmani, Saad Z.van de Donk, Niels W. C. J.Nooka, Ajay K.Perrot, AuroreQi, KeqinHodin, CarolineUhlar, ClarissaZuppa, AthenaChastain, KatherineDoyle, MargaretMaria-Victoria, Mateos
- [26] Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myelomaCANCER, 2023, 129 (13) : 2035 - 2046Martin, Thomas G.Mateos, Maria VictoriaNooka, AjayBanerjee, ArnobKobos, RachelPei, LixiaQi, MingVerona, RalucaDoyle, MargaretSmit, JenniferSun, WeiliTrancucci, DanielleUhlar, Clarissavan de Donk, Niels W. C. J.Rodriguez, Cesar
- [27] Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Usmani, Saad ZafarKarlin, LionelBenboubker, LotfiNahi, HarethSan-Miguel, JesusTrancucci, DanielleQi, KeqinStephenson, TaraPerales-Puchalt, AlfredoChastain, KatherineChari, Ajai
- [28] Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple MyelomaBRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 35 - 36Popat, RakeshUsmani, Saad Z.Garfall, Alfredvan de Donk, NielsNahi, HarethSan-Miguel, Jesus F.Oriol, AlbertNooka, AjayMartin, ThomasRosinol, LauraChari, AjaiKarlin, LionelBenboubker, LotfiMateos, Maria-VictoriaBahlis, NizarMoreau, PhilippeBesemer, BrittaMartinez-Lopez, JoaquinSidana, SurbhiPei, LixiaTrancucci, DanielleVerona, RalucaGirgis, SuzetteOlyslager, YunsiJaffe, MindyUhlar, ClarissaStephenson, TaraVan Rampelbergh, RianBanerjee, ArnobGoldberg, Jenna D.Kobos, RachelKrishnan, Amrita
- [29] Managing infections, hypogammaglobulinemia, and neutropenia during treatment with teclistamab in relapsed/refractory multiple myeloma: nurse-led experience from the MajesTEC-1 studyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S315 - S315Catamero, DonnaBenito, Patricia BlazquezShenoy, SamanthaChastain, KatherineBanerjee, ArnobQi, KeqinSkerget, SheriDoyle, MargaretKruyswijk, Sandy
- [30] Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (03): : 194 - 202Martin, Thomas G.Moreau, PhilippeUsmani, Saad Z.Garfall, AlfredMateos, Maria -VictoriaSan-Miguel, Jesus F.Oriol, AlbertNooka, Ajay K.Rosinol, LauraChari, AjaiKarlin, LionelKrishnan, AmritaBahlis, NizarPopat, RakeshBesemer, BrittaMartinez-Lopez, JoaquinDelforge, MichelTrancucci, DaniellePei, LixiaKobos, RachelFastenau, JohnGries, Katharine S.van de Donk, Niels W. C. J.